Valuation: Sight Sciences, Inc.

Market Cap 283M 247M 229M 210M 397M 27.26B 404M 2.73B 1.07B 13.31B 1.06B 1.04B 45.96B P/E 2026 *
-8.15x
P/E 2027 * -10.3x
Enterprise Value 283M 247M 229M 210M 397M 27.26B 404M 2.73B 1.07B 13.31B 1.06B 1.04B 45.96B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 2.96x
Free-Float
80.02%
Yield 2026 *
-
Yield 2027 * -
1 day-2.60%
1 week-3.76%
Current month-5.54%
1 month+2.20%
3 months+25.18%
6 months-17.95%
Current year-35.44%
1 week 5
Extreme 5
5.5
1 month 4.98
Extreme 4.975
5.89
Current year 3.38
Extreme 3.378
8.19
1 year 3.11
Extreme 3.11
9.24
3 years 1.04
Extreme 1.04
9.31
5 years 1.04
Extreme 1.04
42.57
10 years 1.04
Extreme 1.04
42.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 56 2009-12-31
Chief Executive Officer 51 2009-12-31
Director of Finance/CFO 43 2025-11-04
Director TitleAgeSince
Director/Board Member 64 2025-04-20
Director/Board Member 58 2020-05-31
Director/Board Member 51 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Sell

Founder

-7,418 0.0136%
7/6/26 Sell

General Counsel

-12,733 0.0234%
7/2/26 Sell

Chief Operating Officer

-24,184 0.0444%
Change 5-day change 1-year change 3-year change Capi.($)
-2.79%-3.76%+44.63%-30.05% 283M
+2.23%+8.40%-15.51%-4.84% 172B
+0.44%+0.78%-5.59%-2.52% 107B
+1.23%+3.35%+6.53%+63.21% 59.92B
+0.63%+7.25%-9.92%-36.51% 44.07B
-1.18%+0.51% - - 34.76B
-1.37%+3.54%-7.72%-43.54% 30.09B
+0.10%+2.80%+64.09%-5.22% 25.61B
+0.11%+2.40%-2.70%-18.07% 20.86B
-0.58%+2.91%-1.03%-2.66% 21.55B
Average -0.12%+2.83%+8.09%-8.91% 51.62B
Weighted average by Cap. +0.82%+3.36%-4.09%-1.68%

Financials

2026 *2027 *
Net sales 86.03M 75.2M 69.55M 63.82M 121M 8.29B 123M 829M 326M 4.05B 323M 316M 13.98B 95.66M 83.61M 77.33M 70.96M 134M 9.22B 137M 922M 362M 4.5B 359M 351M 15.54B
Net income -34.77M -30.4M -28.11M -25.79M -48.82M -3.35B -49.67M -335M -132M -1.64B -131M -128M -5.65B -28.69M -25.08M -23.19M -21.28M -40.28M -2.76B -40.98M -277M -109M -1.35B -108M -105M -4.66B
Net Debt - -
Logo Sight Sciences, Inc.
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Employees
186
Date Price Change Volume
26-07-17 US$5.170 -0.58% 17,731
26-07-16 US$5.200 -0.95% 124,884
26-07-15 US$5.250 +3.96% 128,883
26-07-14 US$5.050 -5.43% 107,207
26-07-13 US$5.340 +0.38% 92,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.200USD
Average target price
8.750USD
Spread / Average Target
+68.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SGHT Stock